CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with belatacept

This publication has 21 references indexed in Scilit:

• Increased Pretransplant Frequency of CD28+ CD4+ TEM Predicts Belatacept-Resistant Rejection in Human Renal Transplant Recipients
  American Journal of Transplantation, 2017
• Twenty years of evolving trends in racial disparities for adult kidney transplant recipients
  Kidney International, 2016
• Belatacept and Long-Term Outcomes in Kidney Transplantation
  New England Journal of Medicine, 2016
• The Allo- and Viral-Specific Immunosuppressive Effect of Belatacept, but Not Tacrolimus, Attenuates With Progressive T Cell Maturation
  American Journal of Transplantation, 2014
• Comparison of the Effect of Standard and Novel Immunosuppressive Drugs on CMV-Specific T-Cell Cytokine Profiling
  Transplantation, 2013
• Access and Outcomes Among Minority Transplant Patients, 1999-2008, with a Focus on Determinants of Kidney Graft Survival
  American Journal of Transplantation, 2010
• Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
  American Journal of Transplantation, 2010
• A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)
  American Journal of Transplantation, 2010
• Cell-Mediated Immunity to Predict Cytomegalovirus Disease in High-Risk Solid Organ Transplant Recipients
  American Journal of Transplantation, 2009
• Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent Era
  American Journal of Transplantation, 2004